Mediastinal node removal versus sparing nodes for early lung nodule
Part of Cancer, Lungs & breathing clinical trials.
This trial compares two surgical approaches for people with a single small, noncancer-looking lung nodule (a GGN) that is diagnosed as very early lung cancer. It aims to see whether removing mediastinal lymph nodes—or leaving them alone—can lead to better outcomes with less harm.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your thin-slice CT scan shows one ground-glass nodule (GGN) with a ratio (C/T) of 0.5 or less
- There is no evidence of lung cancer spread to nearby lymph nodes on imaging
- You have very early lung cancer (stage IA NSCLC) diagnosed before surgery or during surgery
- You have not had other cancers in the past 5 years and have not had lung surgery before
- You have not had chemo, radiation, or other cancer treatments before your planned surgery
- You do not have serious lung scarring or severe lung disease (like interstitial pneumonitis, pulmonary fibrosis, or severe emphysema) and you do not have an active infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two ways of removing lymph nodes during lung cancer surgery after you've had pre-surgery immunotherapy and chemotherapy. It aims to see if taking only a few key lymph nodes (instead of all of them) is just as effective and leads to fewer side effects.
This trial compares removing fewer lymph nodes during surgery for early-stage non-small cell lung cancer. It is for people with a small tumor (2 cm or less) that has both solid and ground-glass parts.
This study compares two ways of removing lymph nodes during surgery for early-stage lung cancer that shows up as a ground-glass nodule. The goal is to see which approach gives patients a better long-term outlook.
This trial compares two ways of doing lung cancer surgery for early-stage tumors in the left lung. Some participants will have more lymph nodes removed (station 4L) and others will not, to see if the extra removal helps prevent the cancer from coming back.
This trial looks at complications from removing lymph nodes during surgery for non-small cell lung cancer. It may help doctors understand how to make surgery safer.
This study tests a new way to decide which lymph nodes to remove during lung cancer surgery. The goal is to make surgery more precise and reduce side effects while still effectively removing cancer.
Hear when a new Lung Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.